Clinical Trials

364 enrolled

Triple Negative Breast Neoplasms

NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

544 enrolled

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

NCT07497386 2026-03-27

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

150 enrolled

Unresectable Locally Recurrent Breast Cancer

NCT06765590 2026-03-09

Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

Phase NA Recruiting

24 enrolled

Breast Neoplasms

NCT07208149 2026-02-12

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

42 enrolled

Triple Negative Breast Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

220 enrolled

Triple Negative Breast Neoplasms

NCT06009627 2026-02-10

Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Phase 2/3 Completed

119 enrolled

Breast Neoplasms

NCT07196774 2026-01-30

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

740 enrolled

Early-stage or Locally Advanced HER2-positive Breast Cancer

NCT07209436 2026-01-22

Impact of Pectoral Versus Paravertebral Blocks on Pain and Physical Well-Being in Implant-Based Breast Reconstruction

Phase NA Recruiting

212 enrolled

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms

NCT06220214 2026-01-15

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT07111832 2025-12-18

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

400 enrolled

Triple Negative Breast Neoplasms

NCT07130383 2025-11-18

A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

BreastOther solid neoplasm

210 enrolled

Advanced Breast Cancer

NCT05634954 2025-10-23

Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

Phase 1 Withdrawn

Phase 3 Active not recruiting

Breast Neoplasms

NCT06449027 2025-10-01

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

211 enrolled

Breast Cancer Subjects

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT07169994 2025-09-12

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Phase 2 Active not recruiting

414 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06198751 2025-08-19

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

104 enrolled

Breast Neoplasms

NCT07008976 2025-08-14

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

246 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms

NCT04778839 2025-08-06

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Phase 1 Recruiting

98 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms

NCT07106112 2025-08-06

COMET

Phase NA Recruiting

110 enrolled

Breast Neoplasms

NCT06172127 2025-07-29

DEMETHER

165 enrolled

Breast Neoplasms

NCT07003074 2025-06-25

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

642 enrolled

Breast Neoplasms

NCT06199895 2025-06-03

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

BreastGastrointestinalThoracic

25 enrolled

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Phase 2 Active not recruiting

78 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms

NCT06948539 2025-04-29

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

66 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Phase 3 Not yet recruiting

312 enrolled

Breast Neoplasms

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

240 enrolled

Breast Neoplasms

NCT03936933 2025-02-17

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

Phase 3 Terminated

6 enrolled

Breast Neoplasms

NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Phase 1 Terminated

3 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

NCT06143553 2024-11-29

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

168 enrolled

Breast Neoplasms

NCT06452706 2024-11-19

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

42 enrolled

Breast Neoplasms

NCT06685796 2024-11-13

A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

120 enrolled

Advanced Triple-Negative Breast Cancer

NCT05911958 2024-11-04

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

66 enrolled

HER2 Low Breast Carcinoma

NCT06633601 2024-10-09

MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer

Phase 1 Recruiting

30 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms

NCT05830097 2024-08-26

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

260 enrolled

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

NCT06561607 2024-08-20

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Phase 3 Not yet recruiting

542 enrolled

Breast Neoplasms

NCT06389006 2024-05-23

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

79 enrolled

Breast Neoplasms

NCT06202261 2024-03-12

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

154 enrolled

Breast Neoplasms

NCT05711030 2024-02-20

TPVB

Phase NA Unknown

68 enrolled

Breast Neoplasms

NCT04431674 2023-12-13

USmBRT-B

Phase 1 Completed

20 enrolled

Breast Neoplasms

NCT06115902 2023-11-29

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Phase 1 Recruiting

150 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT06078670 2023-10-12

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

96 enrolled

BreastGastrointestinal

Intestinal Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05755048 2023-09-01

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 3 Unknown

314 enrolled

Breast Neoplasms

NCT05845138 2023-08-01

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Phase 1/2 Unknown

116 enrolled

Breast Neoplasms

NCT05110170 2023-05-16

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Phase 3 Completed

188 enrolled

Breast Neoplasms

NCT03121989 2023-03-30

LABC

Phase 1 Withdrawn

Breast Neoplasms

NCT04382352 2023-03-24

B002-101

Phase 1 Completed

23 enrolled

Breast Neoplasms

NCT04924699 2023-03-17

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2/3 Unknown

350 enrolled